Incidence Of Decompensation Research Articles

Incidence of 1-year mortality, heart failure admissions and decompensation in patients with heart failure followed in HF units in Spain. Differences according to type of units

Abstract Introduction Heart failure is a serious health problem and continues to have a high mortality and incidence of decompensation, despite advances in its management. The introduction of specific multidisciplinary HF units has improved the management of patients with this disease, thanks to better organization and management of available diagnostic and therapeutic resources. The HF Association of the ESC and the Spanish Society of Cardiology have defined 3 types of HF units (community, specialized, and advanced) according to their structure, complexity, and portfolio of services. Purpose To analyze in a contemporary registry of patients with HF followed up in HF units in Spain whether the results in terms of mortality and HF decompensations during follow-up are similar or different between the 3 types of units. Methods We analyzed data from the registry of the SEC-Excelente-IC quality accreditation program of the Spanish Society of Cardiology, with 1,716 patients with HF included between 2019 and 2021 by 45 SEC-accredited HF units. Patients were included consecutively in two 1-month cutoffs (March and October) in that period. Units were defined as community, specialized, and advanced according to ESC HFA and SEC criteria. We compared the incidence of death, HF admissions and total decompensations at 1-year follow-up between community and specialized/advanced units. Results Of the 1716 patients, 55.5% were treated in community units, 65.9% in advanced units, and 20.9% in advanced HF units. Figure 1 shows the main characteristics and treatment used in the 3 types of units. The community units treated older patients and more HFpEF, and the use of NRA and AID was lower, with no differences in the remaining characteristics, comorbidities, or treatments (Figure 1). Figure 2 shows the incidence of events at 1 year. Total mortality was 27.5% in community and 15.5% in specialized/advanced (p<0.001). HF admissions (39.7 vs 29.2%; p=0.019), HF decompensations without admission (16.4 vs 11.3%; p=0.074), total decompensations (56.1 vs 40.5%; p=0.003), and combined HF death/admissions (45.2 vs 31.4%; p=0.005) were statistically higher in community units. Control in specialized/advanced units was an independent protector factor for all events (mortality: HR 0.59, 0.43-0.82; p=0.002; HF admissions: HR 0.61, 0.42-0.90; p=0.012; total HF decompensations: HR 0.58, 0.42-0.81; p=0.001). Conclusions One-year prognosis of HF patients continues to be poor, with high rates of mortality and decompensations. Patients attended in community HF units was significantly worse in our country during the study period. Although this may be due in part to the small differences between the characteristics of the patients followed in the different types of units, it seems necessary to improve the network organization of HF care with the aim of achieving greater equity in the treatment of HF in Spain.

Heart failure and advanced chronic kidney disease: differences in characteristics, treatment and outcomes in patients with glomerular filtration rate greater or less than 30 ml/minute/m2

Abstract Introduction Heart failure (HF) is a serious health problem and continues to have a high mortality and incidence of decompensation, despite advances in its management. Chronic kidney disease (CKD) is very prevalent in patients with HF, hinders their treatment and worsens their prognosis, especially when it is advanced CKD (glomerular filtration rate-GFR <30 ml(min/m2). It is important to know the differential characteristics of these patients to improve their management. Purpose To analyze in a contemporary registry of HF patients followed in specialized HF units in Spain the differences in clinical characteristics and treatment between patients with HF and advanced CKD. Methods We analyzed data from the registry of the SEC-Excelente-IC quality accreditation program of the Spanish Society of Cardiology, with 1716 patients with HF included between 2019 and 2021 by 45 specialized HF units accredited by the SEC. Patients were included consecutively in two 1-month cutoffs (March and October) in that period. The clinical and demographic characteristics and comorbidities of the patients were compared according to GFR < or > 30ml/min/m2. Results Of the 1,716 patients, 11.1% had a GFR<30 and 88.9% >30 mL/min/m2. Figure 1 shows the main clinical characteristics and comorbidities of the 2 groups. Median LVEF was similar in both groups: 42 (30-58) vs 38% (29-54). The group with advanced CKD was older (77±9.6 vs 70.5±12.6 years; p<0.001), had greater HF severity (more admissions for HF in the last year, worse NYHA functional class and longer evolution time), and a higher prevalence of coronary heart disease, hypertension, diabetes mellitus, cognitive impairment, anemia, iron deficiency and hyponatremia. There were no differences in sex, BMI, serum potassium or other comorbidities (Figure 1). Figure 2 shows the treatment received in each group. Patients with GFR <30 received in a significantly lower proportion all drugs for HF (p<0.001), except diuretics and potassium binders (ACEI/ARA, sacubitril-valsartan, MRA, beta-blockers, digoxin and SLGT2 inhibitors), and less cardiac rehabilitation (5.2 vs 10.4%; p=0.029). Incidence of one-year mortality was significantly higher in patients with GFR<30 ml/min/m2 (37.2 vs 14.4 per 100 persons-year, p<0.001), as were HF hospitalizations (61.3 vs 33.0; p<0.001) and HF decompensations without hospitalization (24.1 vs 11; p<0.001). Conclusions In our contemporary cohort of real-life HF patients, the prevalence of advanced CKD was 11.1%. These patients had a higher severity of HF, despite which, the utilization of HF drugs, including SGLT2 inhibitors was much lower than in those with GFR >30 ml/min/m2. One-year mortality, HF hospitalization and HF decompensations were almost 3-times higher. This treatment trend needs to be modified to improve the prognosis of these patients.

Hyper-Selective Posterior Fusion is Recommended When the Modified S-Line is Positive in Lenke 5C Adolescent Idiopathic Scoliosis.

Postoperative coronal decompensation and less fusion level are dilemmas and the proper selective posterior fusion (SPF) strategy should be investigated. We proposed a parameter, modified S-line, and aimed to investigate if the modified S-line could predict postoperative coronal decompensation in patients with Lenke 5C adolescent idiopathic scoliosis (AIS). This is a retrospective radiographic study and Lenke 5C AIS patients undergoing SPF during the period from September 2017 to June 2021 were included. The modified S-line was defined as the line linking the centers of the concave-side pedicles of the upper end vertebra (UEV) and lower end vertebra (LEV) at baseline. A modified S-line tilt to the right is established as modified S-line+ (UEV being to the right of the LEV). The patients were further categorized into two groups: the Cobb to Cobb fusion group and the Cobb-1 to Cobb fusion group. Outcomes including thoracic Cobb angle, TL/L Cobb angle, coronal balance, upper instrumented vertebra (UIV) translation, lower instrumented vertebra (LIV) translation, UIV tilt, LIV tilt, LIV disc angle, thoracic apical vertebral translation, lumbar apical vertebral translation (L-AVT), L-T AVT ratio, L-T Cobb were measured at baseline, immediately after surgery, and the last follow-up. Radiographic parameters and the incidence of both proximal and distal decompensation between the two groups were compared by chi-square test. Among 92 patients, 48 were modified S-line+ and 44 were modified S-line-. Modified S-line+ status was identified as a risk factor for postoperative proximal decompensation (p = 0.005) during follow-up. In Cobb to Cobb group, a higher occurrence of proximal decompensation in individuals with modified S-line+ status (p = 0.001) was confirmed. Also, in the Cobb to Cobb group with baseline modified S-line+ status, patients presenting decompensation showed a significantly larger baseline of the UIV tilt and postoperative disc angle below the lower instrumented vertebra. However, In Cobb-1 group, the incidence of decompensation after surgery showed no association with baseline modified S-line tilt status (p = 0.815 and 0.540, respectively). The modified S-line could serve as an important parameter in surgical decision-making for Lenke 5C AIS patients. Cobb to Cobb SPF is not recommended with a modified S-line+ status, and the Cobb-1 to Cobb fusion may serve as a potential alternative.

Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter?

Transition from compensated to decompensated cirrhosis, defined by overt clinical signs, represents a turning point in the clinical course of the disease. In fact, while compensated cirrhosis is a silent disease characterized by long survival, decompensated cirrhosis is associated with symptoms markedly reducing the quality of life and with a median survival of 2–4 years. Therefore, identifying predictors of decompensation and investigating potential interventions for its prevention is a major objective. Mechanisms and incidence of decompensation, together with its predictors, are summarized here, with regard to the etiology of the disease. In a total of 92 studies including 105 cohorts and 152,320 patients, the mean ± SD 5-year decompensation rate was 24.5 ± 13.6%. The 5-year decompensation rate was significantly different across different etiologies, ranging from 12.8% for biliary etiologies to 33.6% in alcoholic liver disease (p < 0.0001). The most frequently reported significant predictors of decompensation were liver function, portal hypertension, and inflammation/fibrosis indicators. Etiologic treatment was associated with significant risk reduction. While the risk of decompensation significantly varies across different etiologies of cirrhosis, etiology per se has not been properly studied as a decompensation predictor. Although decompensation appears to be related more to inflammation/fibrosis and portal hypertension, the causing factors may determine different activation intensity of the decompensating mechanisms.

Impact of family history of metabolic traits on severity of non‐alcoholic steatohepatitis related cirrhosis: A cross‐sectional study

Familial aggregation of metabolic traits with fatty liver disease is well documented. However, there is scarcity of data regarding such association with non-alcoholic steatohepatitis (NASH)-related cirrhosis. This study was aimed to explore the association of family history of metabolic traits with severity of cirrhosis. In a cross-sectional study, all consecutive patients with NASH-related cirrhosis presenting to our tertiary care centre were included. Family history, personal history, demographic characteristics, medical history, anthropometric measurements and laboratory data were recorded. Of the 1133 cirrhotics (68.1% males, age 51.4±10.9years); 779 (68.8%) had family history for metabolic traits. These patients had lower age at diagnosis (45.4±10.6 vs 49.6±11.2years), higher Child-Turcotte-Pugh (CTP) score (7.8±1.9 vs 6.6±1.5), higher model for end stage liver disease (MELD) score (12.9±6.1 vs 10.9±4.1) and more incidence of decompensation in the form of ascites (46.3% vs 25.7%), jaundice (12.1% vs 6.2%) and hepatic encephalopathy (26.1% vs 11.0%). Patients with family and personal history of metabolic traits, had an increased risk of an early diagnosis of cirrhosis at<45years of age (OR: 3.1, 95% CI 2.1-4.4), CTP≥10 (OR: 4.6, 95% CI 2.3-9.1), MELD>15 (OR: 6.6, 95% CI 3.8-11.5) with ≥1 features of decompensation (OR: 4.2, 95% CI 2.9-6.1). Family history of diabetes alone, also had higher risk of cirrhosis with MELD>15 (OR: 4.3, 95% CI 2.4-5.3, P<.001). Family and personal history of metabolic traits are associated with early age at diagnosis of cirrhosis with more severity and decompensation and so, has a prognostic importance in NASH-related cirrhotics.

The individualized dosimetry in the radioembolization of hepatocarcinoma with 90Y-microspheres

The individualized dosimetry in the radioembolization of hepatocarcinoma with 90Y glass microspheres was introduced in my institution to plan patient treatment as in external beam radiotherapy. We started with a retrospective analysis of 99mTc-MAA simulation SPECT images of strictly selected patients treated with standard 120 Gy to liver lobe. We determined dose-toxicity and dose response correlation and NTCP and TCP. A decompensation risk of 15% was considered acceptable, corresponding to NTCP 15 = 75 Gy, averaged on the whole non tumoral organ volume. A TCP(50%) was found at about 500 Gy, but strongly dependent upon lesion size. Such planning paradigm was then prospectically applied to 116 less selected patients. With respect to the 120 Gy to lobe indication, administered activity was, on the average, doubled in half of patients, reduced of 50% in a quarter of patients. The decompensation incidence was maintained below 15% as planned. TCP of the second cohort was compatible with the first one, while NTCP was shifted to a lower NTCP 15 = 60 Gy. After stratification of patients with (PVT) vs without Portal Vein Thrombosis (NO PVT), in the first PVT subgroups, where lesion had the same size distribution, treatment planning improved median survival from 8 to 12 months, close to significance with Mantel Cox test ( p = 0.067). In the NO PVT subgroups, the median survival was 17 vs 15 months (n.s.) i.e. maintained despite the larger tumor size. Such encouraging results were obtained despite methodological limits: absence of SPECT scatter correction, and observed mismatch between simulation and 90Y PET therapy biodistribution.

PTU-088 De Novo Cirrhosis in Old Age is Associated with Significant Delays in Diagnosis, High Incidence of Decompensation at Presentation and High Mortality

Introduction Mortality related to end-stage liver disease is increasing. Coupled with an ageing population, this will lead to increasing numbers of those aged over 65 with a de novo diagnosis of cirrhosis. However, the incidence and clinical behaviour of cirrhosis in old age is not well understood. Our aim was to evaluate and elucidate the characteristics of cirrhosis in elderly patients. Methods All patients aged over 65 with a diagnosis of cirrhosis at our institution were identified using the health board electronic record. Data on patient demographics, date and method of diagnosis, liver function tests (LFTs), MELD scores, presence of decompensation and outcomes (varices, renal impairment, hepatocellular carcinoma [HCC], death) were collected and analysed. Results 395 cirrhotics aged over 65 were identified. Clinical details were unavailable for 12, 7 had received a liver transplant and 81 were first diagnosed under 65 hence excluded from analysis. Median age was 74 (65–92) and 179/295 (60.7%) were male. The commonest aetiologies of cirrhosis were alcohol (86/295), cryptogenic (81/295) and NASH (62/295). Mode of diagnosis was a combination of laboratory and imaging features (USS, CT or MRI) in 86.8%, liver biopsy in 8.8% and fibroscan in 4.4%. Abnormal LFTs prior to diagnosis were found in 90.5%. Importantly, median delay in diagnosis of cirrhosis from first abnormal LFT was 72 months (1–168). Consequently, 54.6% were decompensated at first presentation. For the cohort, median MELD score was 9 (6–40) at diagnosis. In terms of complications, 139/295 (47.1%) developed ascites, 41/295 (13.9%) had atleast one episode of hepatic encephalopathy and 93/295 (31.5%) developed varices of whom, 24.7% bled. Renal impairment was common, occurring in 164/295 (55.6%). This comprised one or more episodes of acute kidney injury (AKI) in 113/164 (68.9%) and pre-existing CKD in the remainder. Importantly, HCC was diagnosed in 61/295 (20.7%); identified at diagnosis of cirrhosis in 72.1%. Active treatment for HCC occurred in 57.5%; the remainder palliated. Over half the cohort (58.8%) had died at the time of analysis, with median time from diagnosis of cirrhosis to death 13 months (0–116). In the compensated cirrhotics the median was 26 months versus only 9 months in those decompensated at presentation (p = 0.0027). Conclusion De novo cirrhosis in the elderly is associated with significant delays in diagnosis from time of first abnormal LFT, high incidence of decompensation, renal impairment and HCC. Consequently short term mortality is high. Abnormal LFTs should therefore not be ignored. Furthermore, in those with established cirrhosis, close attention should be paid to renal function and potential impact of concomitant diseases and polypharmacy on this. Disclosure of Interest None Declared

Impact of portal hemodynamics on Doppler ultrasonography for predicting decompensation and long-term outcomes in patients with cirrhosis

Objective: Significance of portal hemodynamics for non-invasive marker of cirrhosis remains unclear. The aim was to determine the value of portal hemodynamics on Doppler ultrasound for predicting decompensation and prognosis in cirrhosis. Methods: This retrospective study comprised 236 cirrhotic patients (132 males, 104 females; age 63.7 ± 11.3 years; 110 compensated, 126 decompensated). Clinical data, including Doppler findings, were analyzed with respect to decompensation and prognosis. The median follow-up period was 33.2 months (0.1–95.4). Results: Fifty-three patients developed clinical decompensation, 13 patients received liver transplantation, and 71 died. Higher model for end-stage liver disease score (p < 0.001) at baseline was the significant factor for the presence of decompensation. Higher alanine transaminase (p = 0.020), lower albumin (p = 0.002) and lower mean velocity in the portal trunk (p = 0.038) were significant factors for developing decompensation (best cut-off value: Alanine transaminase > 31 IU/L, albumin < 3.6 g/dL, and portal trunk < 12.8 cm/s). The cumulative incidence of decompensation was higher in patients with portal trunk < 12.8 cm/s (22.5% at 1 year, 71.2% at 5 years) than those without (6.9% at 1 year, 35.4% at 5 years; p < 0.001). The significant prognostic factors were hepatocellular carcinoma (p = 0.036) and lower albumin (p = 0.008) for compensated patients, and reversed portal flow (p = 0.028), overt ascites (p < 0.001), and higher bilirubin (p < 0.001) for decompensated patients. Conclusion: Portal hemodynamics offer a non-invasive marker for decompensation and prognosis of cirrhosis, suggesting a future direction for practical management.

809 The Natural History of Chronic Hepatitis C. an Updated Look At the Rate of Progression to Cirrhosis and the Incidence of Decompensation in a Large U.S. Health Maintenance Organization

809 The Natural History of Chronic Hepatitis C. an Updated Look At the Rate of Progression to Cirrhosis and the Incidence of Decompensation in a Large U.S. Health Maintenance Organization

Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis

Our aim was to assess the predictive value of liver stiffness (LS), measured by transient elastography (TE), for clinical outcome in human immunodeficiency virus / hepatitis C virus (HIV/HCV)-coinfected patients with compensated liver cirrhosis. This was a prospective cohort study of 239 consecutive HIV/HCV-coinfected patients with a new diagnosis of cirrhosis, done by TE, and no previous decompensation of liver disease. The time from diagnosis to the first liver decompensation and death from liver disease, as well as the predictors of these outcomes, were evaluated. After a median (Q1-Q3) follow-up of 20 (9-34) months, 31 (13%, 95% confidence interval [CI]: 9%-17%) patients developed a decompensation. The incidence of decompensation was 6.7 cases per 100 person-years (95% CI, 4.7-9-6). Fourteen (8%) out of 181 patients with a baseline LS < 40 kPa developed a decompensation versus 17 (29%) out of 58 with LS ≥ 40 kPa (P = 0.001). Factors independently associated with decompensation were Child-Turcotte-Pugh (CTP) class B versus A (hazard ratio [HR] 7.7; 95% CI 3.3-18.5; P < 0.0001), log-plasma HCV RNA load (HR 2.1; 95% CI 1.2-3.6; P = 0.01), hepatitis B virus coinfection (HR, 10.3; 95% CI, 2.1-50.4; P = 0.004) and baseline LS (HR 1.03; 95% CI 1.01-1.05; P = 0.02). Fifteen (6%, 95% CI: 3.5%-9.9%) patients died, 10 of them due to liver disease, and one underwent liver transplantation. CTP class B (HR 16.5; 95% CI 3.4-68.2; P < 0.0001) and previous exposure to HCV therapy (HR 7.4; 95% CI 1.7-32.4, P = 0.007) were independently associated with liver-related death; baseline LS (HR 1.03; 95% CI 0.98-1.07; P = 0.08) was of borderline significance. LS predicts the development of hepatic decompensations and liver-related mortality in HIV/HCV-coinfection with compensated cirrhosis and provides additional prognostic information to that provided by the CTP score.

Selective Thoracic Fusion in Adolescent Idiopathic Scoliosis

Analysis of multicenter, prospectively collected data. To determine how selection of the lowest instrumented vertebra (LIV) relative to the stable vertebra (SV) and the end vertebra (EV) effects correction of the main thoracic curve, compensatory lumbar curve, and incidence of coronal decompensation after selective thoracic fusion. Traditionally, in Lenke type 1B and 1C curves, the LIV is selected as the SV; however, selecting the LIV continues to be controversial. Inclusion criteria were patients with adolescent idiopathic scoliosis (AIS) with Lenke type 1B, 1C, or 3C curves that had a selective thoracic fusion with the LIV from T11 to L1 (n=172). The patients were divided into three curve patterns on the basis of the relative position of SV and EV. Group SBE (stable below end) (n=93) had SV below EV, group SAE (stable at end) (n=66) had SV at the EV, and group EBS (end below stable) (n=13) has EV below SV. In addition, each group was divided into six subgroups based on the selected LIV: LIV above SV, at the SV, below SV, above EV, at the EV, and below EV. Each was compared for preoperative and 2-year postoperative radiographic parameters and clinical data. In group SBE, the 2-year postoperative thoracic curve correction rate when the LIV was below the EV (64%+16%) was significantly greater than when the LIV was at the EV (54%+13%; P<0.001). The 2-year postoperative spontaneous lumbar curve correction (SLCC) rate similarly correlated with the LIV selection subgroups, 52%+20% and 43%+19%, respectively (P=0.03). In group SAE, the 2-year postoperative thoracic curve correction rate when the LIV was below the EV/SV (64%+14%) was significantly greater than when the LIV was at the EV/SV (52%+14%; P=0.004). The 2-year postoperative SLCC rate for group SAE similarly correlated with the LIV selection subgroup, 56%+16% and 38%+21%, respectively (P<0.01). In group EBS, the 2-year postoperative thoracic curve correction and SLCC rates were not significantly different among the LIV selection subgroups; however, the incidence of decompensation was 38%. When performing a selective thoracic fusion of Lenke type 1B, 1C, and 3C AIS curves in which the SV was at/or below the EV, the greatest correction of the main thoracic and compensatory lumbar curves occurred when the LIV was at/or at least one level distal to the SV. This more distal LIV did not result in an increased rate of truncal imbalance.

Cotrel-Dubousset instrumentation in idiopathic scoliosis.

Although well accepted in the patient undergoing Harrington instrumentation, the validity of King's criteria in patients undergoing correction of idiopathic scoliosis using the Cotrel-Dubousset system has been questioned. The cases of 64 patients with Type II (N = 40) and Type III (N = 24) idiopathic scoliosis treated with Cotrel-Dubousset instrumentation were reviewed. The average curve correction for Type II spinal curvature was 69.4% after surgery and 57.8% at follow-up examination. Decompensation was evident in 40% of the curves that were fused beyond the stable vertebra. However, the patients were only aware of their trunk decompensation if it was larger than 10 mm, and this was found in 35% of the patients. Decompensation occurred in 60% of those that were fused short of or to the stable vertebra. Only 42% of this group were aware of their decompensation. Decompensation was measured to the left of the spine in all patients. The difference between the subgroups based on the choice of distal fusion levels was not statistically significant (P greater than 0.05). The average curve correction for Type III scoliosis was 62.9% after surgery and 54.6% at the time of follow-up examination. There was no correlation between caudal fusion levels and the incidence of decompensation with Type III curves. It was concluded that there was no statistically significant relationship between choice of distal fusion level and the amount of decompensation, thereby indicating that the use of King's criteria for the selection of fusion levels in patients undergoing correction of idiopathic scoliosis using the Cotrel-Dubousset instrumentation may not be useful.